Life Science News

RSS

Roche Diagnostics and Takara Bio enter into license agreement

Roche Diagnostics and Takara Bio, the Shiga (Japan)-based supplier of systems for use in life science research, announced that they have entered into a license agreement for use of the melting curve analysis technology and SYBR Green techniques in their Kits and Instruments for Real Time PCR.

From Roche Sequencing and Life Science 18 Dec 2009

Thermo Fisher Scientific selected as NCS biological and environmental sample repository partner

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has been selected as the National Children’s Study (NCS) biological and environmental sample repository partner. The study examines the effects of environmental influences on the health and development of 100,000 children across the United States, following them from before birth until age 21.

From Thermo Fisher Scientific Inc. 17 Dec 2009

Roche Diagnostics launches new customer training center in Pleasanton, California

Roche Diagnostics announced today the opening of a new west-coast customer training center in Pleasanton, California, as part of an initiative to make state-of-the-art training on diagnostic equipment more accessible to hospitals and independent laboratories on the west and east coasts.

From Roche Sequencing and Life Science 8 Dec 2009

Fluxion Biosciences signs distribution agreement with DI Biotech and Novel Science

Fluxion Biosciences announced today that it has expanded its sales and service network into Asia. The company signed a distribution agreement for its BioFlux™ line with Korea-based DI Biotech. A second agreement with Novel Science covers sales of both the BioFlux and IonFlux™ platforms in Japan. Fluxion has also sold its first BioFlux 1000 system into China.

From Fluxion Biosciences 4 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

Roche, Spanish Department of Health to collaborate in Medical Genome Project

Roche and the Department of Health of Junta de Andalucía, Spain have signed an agreement for a cooperation in the Medical Genome Project (MGP), a research project created to analyse the genomes of people with rare diseases and identify the defective gene or genes causing the disease and its behaviour.

From Roche Sequencing and Life Science 24 Nov 2009

Image of a water flea wins top prize in the 2009 Olympus BioScapes Digital Imaging Competition

A glowing, eerily beautiful image of a water flea with its radiant green "crown of thorns" took top prize in the 2009 Olympus BioScapes Digital Imaging Competition®, the world's foremost forum for showcasing microscope photos and movies of life science subjects. Dr. Jan Michels, a zoologist at the University of Albrecht, Kiel, Germany, took top honors for the image of a water flea, with its defensive "crown of thorns" to protect it against predators. The image reveals not only the exoskeleton, but also interior detail down to the nuclei within its cells, seen as tiny, glowing blue dots. This

From Evident Corporation - Life Sciences 20 Nov 2009

NRC helps Olympus to design and commercialize CARS microscope

The National Research Council Canada (NRC) recently helped Olympus, a world leader in advanced optical microscopy and medical imaging, to design and commercialize a CARS (Coherent Anti-stokes Raman Scattering) microscope.

From Evident Corporation - Life Sciences 16 Nov 2009

New microplate for BioFlux live cell imaging workstations

Fluxion Biosciences introduces a new microplate for its BioFlux live cell imaging workstations, extending their shear flow limits to simulate a variety of pathological vascular conditions. With the new High Shear Plate, the BioFlux systems can be an effective tool in thrombosis and platelet studies, cardiovascular and immunological drug screening and cell/bacteria adhesion research.

From Fluxion Biosciences 11 Nov 2009

World's smallest gastrointestinal videoscope with four-way angulation and NBI

Olympus today introduced the world's smallest gastrointestinal videoscope to offer four-way angulation and Narrow Band Imaging™ (NBI) to detect upper gastrointestinal abnormalities. The super-slim scope is 5.5 mm in diameter at the distal end, as well as the insertion tube, and offers exceptional insertion capability to enhance patient comfort. The scope also features NBI, Olympus' proprietary imaging technology that filters white light to consist of specific wavelength bands enabling enhanced observation of microvessels and subtle changes on the mucosa.

From Evident Corporation - Life Sciences 11 Nov 2009

Olympus Medical Systems and Opitz + Flierl Hospitaltechnik offer complete integrated solutions for operating theatres

Under the leadership of its Systems Integration business unit, Olympus Medical Systems Europa GmbH, Hamburg, together with Opitz + Flierl Hospitaltechnik AG, Heideck near Nuremberg, Germany, have agreed a joint venture to meet the technological challenges of constructing hospital interiors for the future, whilst expanding their positions in the market.

From Evident Corporation - Life Sciences 9 Nov 2009

$1.85 million grant to study how digital games can improve players' health behaviors and outcomes

The Robert Wood Johnson Foundation (RWJF) today announced more than $1.85 million in grants for research that will offer unprecedented insight into how digital games can improve players' health behaviors and outcomes. With funding from RWJF's Health Games Research national program, nine research teams across the country will conduct extensive studies to discover, for example, how the popular dance pad video game Dance Dance Revolution might help Parkinson's patients reduce the risk of falling, how Wii Active might be most effectively implemented in high schools to help overweight students lose weight, how a mobile phone game with a breath interface might help smokers quit or reduce their tobacco use, or how facial recognition games might be designed to help people with autism learn to identify others' emotions.

From Evident Corporation - Life Sciences 6 Nov 2009

Thermo Fisher Scientific announces the availability of its Copeptin assay in Europe

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack.

From Thermo Fisher Scientific Inc. 26 Oct 2009

New nucleic acid test to screen donated blood for HIV-1 Group M RNA approved

Health Canada has approved a new nucleic acid test from Roche Diagnostics to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay.

From Roche Sequencing and Life Science 24 Oct 2009

Olympus introduces Endo Capsule Software for examining high resolution small bowel images

Olympus, a precision technology leader, creating innovative opto-digital solutions in healthcare, life science and consumer electronics products, today announced the introduction of its improved user-friendly Endo Capsule Software version 1.02A, a customized and comprehensive system for examining high resolution small bowel images.

From Evident Corporation - Life Sciences 24 Oct 2009

Thermo Fisher Scientific's revenues decrease by 2% in third quarter 2009

Thermo Fisher Scientific Inc., the world leader in serving science, reported that revenues decreased 2% to $2.53 billion in the third quarter of 2009, compared with $2.59 billion in the 2008 quarter. These results reflect the impact of foreign currency translation, which lowered revenues by 2%, and acquisitions, which increased revenues by 2%. GAAP diluted earnings per share (EPS) were $.53 in 2009, versus $.50 in the year-ago period. GAAP operating income for the 2009 quarter was $275 million, compared with $286 million in 2008, and GAAP operating margin was 10.9%, compared with 11.1% a year ago.

From Thermo Fisher Scientific Inc. 22 Oct 2009

Olympus unveils new surgical instruments for single-incision procedures

Olympus, a precision technology leader, creating innovative opto-digital solutions in healthcare, life science and consumer electronics products, today introduced three new surgical instruments specifically designed for Laparo-Endoscopic Single-Site (LESS) surgery

From Evident Corporation - Life Sciences 19 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

Affymetrix unveils Axiom Genotyping Solution

Affymetrix, Inc. (Nasdaq:AFFX) today announced the launch of the Axiom Genotyping Solution, its next-generation array technology designed to match the significant rise in genetic content generated by government and privately funded sequencing projects.

From Beckman Coulter Life Sciences - Automation and Genomics 15 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009